Get started
Author

Maria Liga

Observed names: Liga, Maria, M Liga, M. Liga
ORCID: 0009-0005-0911-6311
Observed ORCID: 0009-0005-0911-6311
OpenAlex ID: A5029210272
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen
2012 · Maria Liga, Evangelia Triantafyllou, et al. · Transplantation and Cellular Therapy · 79
PDF
Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy
2020 · Eleni Gavriilaki, Tasoula Touloumenidou, et al. · Thrombosis and Haemostasis · 47
Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet
2010 · E.D. Lagadinou, M. Marangos, et al. · Transplant Infectious Disease · 25
A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation
2015 · Ioanna Sakellari, Maria Angelopoulou, et al. · Annals of Hematology · 23
Hematopoietic Stem Cell Transplantation from Alternative Donors for High-Risk Acute Leukemia: The Haploidentical Option
2007 · Franco Aversa, Antonio Tabilio, et al. · Current Stem Cell Research & Therapy · 22
Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia
2010 · A Spyridonidis, M Liga, et al. · Bone Marrow Transplantation · 20
PDF
Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites
2012 · I. Lazana, A. Zoudiari, et al. · Haematologica · 15
EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy
2024 · Eleni Gavriilaki, Ifigeneia Tzannou, et al. · Blood Vessels Thrombosis & Hemostasis · 13
Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients
2023 · Eleni Gavriilaki, Ifigeneia Tzannou, et al. · Blood · 10
Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes
2019 · Eleni Gavriilaki, Evdoxia Koravou, et al. · Blood · 10
Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia
2016 · P Tsirigotis, M Liga, et al. · Bone Marrow Transplantation · 9
Harnessing the immunomodulatory properties of HLA-G for advanced immunotherapies
2025 · Xeni Beli, Nikolaos Savvopoulos, et al. · Frontiers in Immunology · 7
PDF
Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece
2025 · Eleni Gavriilaki, Ifigeneia Tzannou, et al. · Frontiers in Medicine · 7
PDF
Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing
2021 · Eleni Gavriilaki, Eudoxia-Evaggelia Koravou, et al. · Thrombosis Update · 7
PDF
Double trouble: Influenza and pneumococcal vaccine exacerbation of psoriasis in a new‐onset polycythemia vera patient
2020 · Katerina Grafanaki, Eleftheria Vryzaki, et al. · The Journal of Dermatology · 7
A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.
2012 · Alexandros Spyridonidis, Maria Liga · PubMed · 5
The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry
2025 · Ioanna Lazana, Maria Papathanassiou, et al. · Cancers · 4
PDF
Study protocol: Phase I/II trial of induced HLA-G+ regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor
2023 · Memnon Lysandrou, Dionysia Kefala, et al. · Frontiers in Medicine · 4
Nationwide Multicenter Real-World Survey of CAR-T Cell Toxicity Prophylactic and Treatment Management Strategies
2024 · Eleni Gavriilaki, Ifigeneia Tzannou, et al. · Blood · 3
PDF
Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY
2026 · Maria Liga, Dimitrios Tsokanas, et al. · Current Opinion in Immunology · 2
Successful mobilization with plerixafor and autologous hematopoietic SCT in a patient with refractory Hodgkin's lymphoma and Gaucher disease
2010 · A Symeonidis, M Liga, et al. · Bone Marrow Transplantation · 2
Real‐World Outcomes in NPM1 ‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse
2026 · Panagiotis Tsirigotis, Maria Garofalaki, et al. · American Journal of Hematology · 1
Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT
2025 · Jarosław Dybko, Wojciech Szlasa, et al. · Bone Marrow Transplantation · 1
PDF
Topical 5‐fluorouracil 4% resolves anti‐ PD ‐1 induced keratoacanthomas in enteropathy‐associated T‐cell lymphoma allogeneic transplant patient
2024 · Katerina Grafanaki, Zoe Apalla, et al. · International Journal of Dermatology · 1
First-in-human Phase I/ii Clinical Trial of Ig-tregs for Gvhd Prevention
2024 · M. Lysandrou, D. Kefala, et al. · Cytotherapy · 1
Works count: 46
Citation count: 326
H-index: 10
I10-index: 10
Year
Topic
Type